Cited by 23Photodynamic Therapy Research StudiesPorphyrin Metabolism and DisordersPorphyrin and Phthalocyanine Chemistry

Ferrochelatase Deficiency Abrogated the Enhancement of Aminolevulinic Acid‐mediated Protoporphyrin IX by Iron Chelator Deferoxamine

Open access
Palasuberniam, Pratheeba, Kraus, Daniel, Mansi, Matthew, Braun, Alexander, Howley, Richard, Myers, Kenneth A., Chen, Bin·2019·Photochemistry and Photobiology

Abstract

Aminolevulinic acid (ALA) is a prodrug that is metabolized in the heme biosynthesis pathway to produce protoporphyrin IX (Pp IX) for tumor fluorescence detection and photodynamic therapy (PDT). The iron chelator deferoxamine (DFO) has been widely used to enhance Pp IX accumulation by inhibiting the iron‐dependent bioconversion of Pp IX to heme, a reaction catalyzed by ferrochelatase (FECH). Tumor response to DFO treatment is known to be highly variable, and some tumors even show no response. Given the fact that tumors often exhibit reduced FECH expression/enzymatic activity, we examined how reducing FECH level affected the DFO enhancement effect. Our results showed that reducing FECH level by silencing FECH in SkBr3 breast cancer cells completely abrogated the enhancement effect of DFO. Although DFO enhanced ALA‐Pp IX fluorescence and PDT response in SkBr3 vector control cells, it caused a similar increase in MCF 10A breast epithelial cells, resulting in no net gain in the selectivity toward tumor cells. We also found that DFO treatment induced less increase in ALA‐Pp IX fluorescence in tumor cells with lower FECH activity (MDA‐MB‐231, Hs 578T) than in tumor cells with higher FECH activity (MDA‐MB‐453). Our study demonstrates that FECH activity is an important determinant of tumor response to DFO treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/php.13091

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • DFO increases ALA-PpIX fluorescence more after 1 h than after 4 h treatment and there is an inverse correlation between PpIX fluorescence and the enhancement effect of DFO.

    “Particularly, DFO increases ALA-PpIX fluorescence more after 1 h than after 4 h treatment and there is an inverse correlation between PpIX fluorescence and the enhancement effect of DFO.”

    From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [106]

    The Results report that DFO increased ALA-PpIX fluorescence in control cells but not in FECH-knockdown cells, which had higher PpIX fluorescence (sections on DFO treatment and FECH knockdown; page unavailable). This is consistent with the claimed inverse relationship in those cell lines, but the paper does not establish a general inverse correlation. The Flow cytometry Methods describe a 4-hour treatment, not a comparison showing greater enhancement after 1 hour. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Our results indicate that the effects of DFO are dependent on the duration of treatment and FECH expression.

    “Furthermore, our results indicate that the effects of DFO are dependent on the duration of treatment and FECH expression [106,107].”

    From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [106]

    The Results and Discussion report that FECH knockdown abolished DFO’s enhancement of ALA-PpIX fluorescence and that cell lines with lower FECH activity responded less. The Methods describe a 4-hour drug incubation, but the paper does not compare treatment durations or establish that DFO’s effects depend on duration. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Palasuberniam, P., Kraus, D., Mansi, M., Braun, A., Howley, R., Myers, K. A., & Chen, B.
Affiliations
University of the Sciences (US)
Corresponding author
Chen, Bin
Venue
Photochemistry and Photobiology
Publisher
Wiley
Published
2019-03-15
Volume
95
Issue
4
Pages
1052-1059
ISSN
  • 0031-8655 (ISSN-L)
  • 1751-1097
OpenAlex
W2914538391
Cited by
23
References
38
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 4 · 2019: 1
FWCI
2.76
Type
journal article
Language
en
Open access
Locations
  • Photochemistry and Photobiology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion)
Funders
National Institutes of Health (R15EB026208)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
  • Physical Sciences › Materials Science › Materials Chemistry › Porphyrin and Phthalocyanine Chemistry
Keywords
ferrochelatase, deferoxamine, 5-aminolevulinic acid, protoporphyrin IX, heme biosynthesis, photodynamic therapy, iron chelation, breast cancer, SK-BR-3 cells, tumor selectivity
MeSH terms
Aminolevulinic Acid, Breast Neoplasms, Deferoxamine, Epithelial Cells, Female, Ferrochelatase, Humans, Photochemotherapy, Protoporphyrins, Siderophores, Photosensitizing Agents, Gene Silencing, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review